40 results about "C-KIT Gene" patented technology

The invention discloses a c-KIT gene mutation detection liquid-phase chip, which comprises tag sequence at 5' terminal and ASPE (Allele Specific Primer Extension) primers consisting of specific primers specific to mutational sites at 3' terminal. The specific primers consist of sequences shown in SEQ ID No.10 and SEQ ID No.11 specific to AY502-503dup mutational sites, sequences shown in SEQ ID No.12 and SEQ ID No.13 specific to V560G mutational site, sequences shown in SEQ ID No.14 and SEQ ID No.15 specific to T670I mutational site and/or sequences shown in SEQ ID No.16-SEQ ID No.18specific to D816H/V mutational site, the tag sequence which is selected from sequences shown in SEQ ID No.1-SEQ ID No.9, microballoons which have different color codings and are respectively enveloped with a specific anti-tag sequence and amplification primers. The coincidence ratio of the result of sequencing method with that of the c-KIT gene mutation detection liquid-phase chip reaches up to 100 percent. The c-KIT gene mutation detection liquid-phase chip can simultaneously detect a plurality of mutational sites with excellent signal to noise ratio.

The invention discloses a probe, a primer and a detection kit for detecting C-KIT gene mutation, which comprise the following sequence: SEQ ID NO1-SEQ ID NO3. By utilizing a specific primer and a probe technology, a real-time fluorescent PCR (polymerase chain reaction) system for detecting C-KIT gene mutation is established. The method has the advantages that (1) the sensitivity is high, and 5-10 copied mutation DNA (deoxyribonucleic acid) can be detected; (2) the specificity is strong, 10ng of wild type genome DNA cannot generate non-specific signals; and (3) the detection speed is high, the detection can be finished only in 90 minutes.

The invention relates to the technical field of molecule detection for guiding tumor therapy and in particular discloses a primer used for detecting mutation of exons 9 and 11 of a c-kit gene and application thereof to the identification of the sensitivity of a tumor patient to imatinib (gleevec) medicaments. First, a DNA is extracted from a tumor tissue or a blood sample of a patient; secondly, a target fragment is amplified by the designed primer; and finally, the mutation locuses of the kit exons 9 and 11 are detected by sequencing the target segment so as to guide the therapy on the tumor patient.

The invention discloses a primer, a probe and a kit for detecting mutation of 1675 to 1681 sites of a C-KIT gene. The primer is shown as SEQ ID No.1 to SEQ ID No.2; the probe is shown as SEQ ID No.3.When the kit disclosed by the invention is used for carrying out real-time fluorescence PCR (Polymerase Chain Reaction), the 1675 to 1681 sites of the C-KIT gene can be replaced with mutation of A.

The invention provides a hairpin polyamide compound (I) modified by chiral (S)-beta-hydroxyl-gamma-amino acid, and an application for the same in preparation of anti-tumour medicines. The compound is of a hairpin structure, and contains (S)-beta-hydroxyl-gamma-amino acid residue (S gamma beta-OH) with a specific identification function for the basic group T of DNA (deoxyribonucleic acid); additionally, the compound further contains common N-methylpyrrole residue (Py), N-methylimidazole residue (Im), gamma-amino acid residue and beta-alanine residue. Experiments indicate that the hairpin polyamide compound provided by the invention has a strong killing effect on tumour cells BEL7402 (liver cancer) and MKN45 (poorly-differentiated gastric cancer), and the compound III is the strongest in expression, and has essential significance on research and development for anti-tumour gene targeted medicines down-regulated by chirally-modified polyamide mediate c-kit gene.

The invention discloses a primer, probe and kit for detecting 1737-1738 site mutations of C-KIT genes. The primer is as shown in SEQ ID No. 1-SEQ ID No.2, and the probe is as shown in the SEQ ID No.3.By using the kit disclosed by the invention for performing real-time fluorescence PCR, 1737-1738 site insertion TATGAT mutations of the C-KIT genes can be detected.

The invention discloses a primer, a probe and a kit for detection of C-KIT gene mutation. The primer is represented as the SEQ ID No.1 and the SEQ ID No.2 and the probe is represented as the SEQ ID No.3. By means of the kit for real-time fluorescent PCR, T-replacement mutation on the 1700-1733 loci of C-KIT gene can be detected.

The invention discloses primers, a probe and a kit for detecting mutation of a C-KIT gene at site 1689 to 1718. The primers are as shown in SEQ ID No. 1 and SEQ ID No. 2, and the probe is as shown inSEQ ID No. 3. When the kit provided by the invention is applied to real-time fluorescent PCR, the substitution mutation of GGGTCT at the site 1689 to 1718 of the C-KIT gene can be detected.

The invention discloses primers, probes and kit for detecting a C-kit gene K642E mutation site. The primers, probes and kit comprise a peptide nucleic acid (PNA) probe used for preventing amplification of wild type genes, an upstream primer used for specific amplification of targeting sequences, a downstream primer used for specific amplification of targeting sequences, a probe for detecting the C-kit gene K642E mutation site, a quality control prime pair and a quality control probe. The kit is suitable for various clinical sample types and has the remarkable advantages that specificity is high, sensitivity is high, the experimental period is short, operation is easy, safety is realized, toxicity is avoided, and the cost is low.

The invention discloses a c. A method for detecting mutation of kit gene comprising the follow steps: S1, according to 9, 11, 13 and 17 c-Kit Exon DNA Sequences, designing Specific Amplification Primers; S2, PCR amplification of No. 9, 11, 13 and 17 c by using the specific amplification primers designed in step S1; Kit exon, and the PCR amplified products being digested by enzymes; S3, carrying out cyclic amplification on that enzymatic hydrolysate according to the sequence primer to obtain a Sanger fragment; S4, using the Sanger fragment obtained in the step S3, analyzing No.9, 11, 13 and 17c-Kit exon DNA sequence information through an automatic gene instrument, comparing with wild genotype to find out the mutation site. The invention designs the specific amplification primer, shortensthe length of the primer, improves the specific amplification sensitivity, and intuitively sees whether the target gene amplified by PCR is qualified through the specific amplification primer, therebydeciding whether to carry out the next step and avoiding wasting the reagent.

The invention discloses a primer, a probe and a kit for detecting mutation of 1654 to 1689 sites of a C-KIT gene. The primer is shown as SEQ ID No.1 to SEQ ID No.2; the probe is shown as SEQ ID No.3.When the kit disclosed by the invention is used for carrying out real-time fluorescence PCR (Polymerase Chain Reaction), deletion mutation of the 1654 to 1689 sites of the C-KIT gene can be detected.

The invention relates to a c-KIT somatic mutation gene detecting kit and a detecting method thereof. The kit comprises primers and probes for detecting c-KIT somatic cell gene mutation. The primers and the probes are specifically the primer and the probe for detecting a No. 11 exon of a c-KIT gene, wherein a primer sequence is as shown in SEQ ID NO: 1-6, and a probe sequence is as shown in SEQ IDNO: 7-8; the primer and the probe are used for detecting a No. 9 exon of the c-KIT gene, wherein the primer sequence is as shown in SEQ ID NO: 9-10, and the probe sequence is as shown in SEQ ID NO: 11; the primer and the probe are used for detecting a No. 13 exon of the c-KIT gene, wherein the primer sequence is as shown in SEQ ID NO: 12-14, and the probe sequence is as shown in SEQ ID NO: 15; andthe primer and the probe are used for detecting a No. 17 exon of the c-KIT gene, wherein the primer sequence is as shown in SEQ ID NO: 16-19, and the probe sequence is as shown in SEQ ID NO: 20. Thedetecting kit and the detecting method are far more than similar products in detecting site number, complete in site, high in detecting sensitivity, strong in specificity, high in accuracy, low in cost, and capable of meeting clinical GIST targeted administration c-KIT mutation detection.

The invention provides a kit for detecting the human c-kit gene mutation type. The kit comprises primer pairs shown in SEQ ID NO.1-4 and a probe shown in SEQ ID NO.5. The invention further discloses a method for detecting human c-kit gene exon 17 mutations. The kit and method can accurately detect D816V, D820H, N822I and N822K mutations of the human c-kit gene exon 17, provide a medicine guide for GIST patients, and are good in clinic application prospect.

The invention relates to a primer group, a kit and a method for detecting c-kit gene mutation and belongs to the technical field of biological detection. The primer group comprises a PCR (polymerase chain reaction) amplification primer pair for detecting c-kit gene exon 9, a PCR amplification primer pair for detecting c-kit gene exon 11, a PCR amplification primer pair for detecting c-kit gene exon 13 and a PCR amplification primer pair for detecting c-kit gene exon 17. The novel primer group for detecting c-kit gene mutation can be used for detecting mutation of the c-kit gene exon 9, the exon 11, the exon 13 and the exon 17. The primer group is high in specificity, accuracy and sensitivity in c-kit gene mutation detection and can accurately detect samples with low mutation rate.

The invention discloses a primer combination for detecting mutation of a C-KIT gene in trace tissue. The primer combination comprises a pre-amplification primer group, a primer group for detecting No.9 exon mutation, a primer group for detecting No.11 exon mutation, a primer group for detecting No.13 exon mutation, a primer group for detecting No.14 exon mutation, a primer group for detecting No.17 exon mutation and a primer group for detecting No.18 exon mutation. According to a method, a trace amount of DNA is pre-amplified to obtain a high-concentration DNA template, and the mutation condition of the C-KIT gene in a sample is detected by combining a direct sequencing method; by applying the primer combination to preparation of a detection reagent for detecting mutation of the C-KIT gene, the DNA concentration of the detectable sample is low up to 100 pg, and all mutation of a No.9 exon, a No.11 exon, a No.13 exon, a No.14 exon, a No.17 exon and a No.18 exon of the C-KIT gene can be simultaneously detected. The detection method is high in sensitivity and specificity, low in cost and suitable for C-KIT gene mutation detection on a clinical tumor patient and has the very good clinical application value.

The invention provides a primer for detecting human gastrointestinal stromal tumor C-KIT gene V559A mutation, a detection method and a kit thereof. The detection primer provided by the invention can bind to a specific sequence of the C-KIT gene, and amplifies a mutant sequence. The detection method adopts a detection fluorescent signal group to bind to an amplified fragment to emit a fluorescent signal, and uses a blocking agent specifically binding to the wild type sequence corresponding to the mutation site to inhibit wild type non-specific amplification. The method adopts a competitive allele specific PCR amplification technology to establish a real-time fluorescent PCR kit, which can accurately detect the C-KIT gene V559A mutation. The method of the invention has simple operation, easyresult reading, and high sensitivity, can detect a sample containing 0.001% C-KIT gene V559A mutation, and realizes ultrasensitive detection of the C-KIT gene V559A mutation.

The invention provides a diagnostic kit for detecting human C-Kit gene number 11 exon mutation. The diagnostic kit comprises primer pairs shown as SEQ ID NO.1-283 and a probe shown as SEQ ID NO.284. The invention further discloses a method for detecting human C-Kit gene number 11 exon mutation. The kit and the method can accurately detect all mutation types of human C-Kit gene number 11 exon, provide guidance of medication usage for GIST patients and have good clinic application prospects.